We recently published a list of 10 Jim Cramer Stocks to Watch This Month. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks that Jim Cramer ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

All told, Eli Lilly has tallied up about $23 billion in ... Sales of breast cancer treatment Verzenio also are booming at $5.3 billion, which was a 37% increase from 2023.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes ...

In the fourth quarter, the company's cancer drug, Verzenio, reported sales of $1.6 billion, up 36% year over year. Eli Lilly's immunosuppressant Taltz racked up revenue of $952 million ...

Eli Lilly’s profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s ...